4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings.
加州埃默裏維爾，2024年8月12日（環球新聞社） - 4D分子治療（納斯達克：FDMt，4DMt或公司），一家領先的臨床遺傳藥物公司，致力於釋放遺傳藥物治療大型市場疾病的全部潛力，今天宣佈管理層將參加 H.C. Wainwright 第4屆年度眼科虛擬會議的座談會。管理團隊成員也將爲一對一會議提供服務。
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
H.C. Wainwright第四屆年度在線眼科醫療大會
| Presentation Date: | Thursday, August 15, 2024 |
| Presentation Time: | 12:00 p.m. ET |
| Webcast Link: | Webcast |
| 演示日期： | 2024年8月15日，星期四 |
| 演示時間： | 美國東部時間下午12:00 |
| 網絡鏈接： | 網絡轉播 |
An archived copy of the webcast will be available for up to one year by visiting the "Investors" section of the 4DMT website at .
可通過訪問4DMt網站的「投資者」部分，在一年之內檢索網絡研討會的存檔副本。
About 4DMT
關於4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT's proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.
4DMt是一家領先的臨床遺傳藥物公司，專注於釋放眼科和肺病領域遺傳藥物治療大型市場疾病的全部潛力。4DMT的專有發明平台 Therapeutic Vector Evolution 將諾貝爾獎獲獎技術定向進化的力量與近十億個合成 AAV 殼體派生序列相結合，以發明用於我們的全資和合作產品候選人的定製和演變載體。我們的產品設計、開發和製造引擎幫助我們高效地創建和推進我們多樣化的產品管道，旨在以潛在的治癒療法革新醫學，服務於數百萬患者。目前，4DMt正在推進六個臨床階段和一個臨床前產品候選人，每個產品都旨在治療眼科、肺病和心臟病等罕見和大型市場疾病。此外，4DMt 也通過基因編輯合作推進了中樞神經系統計劃。4D分子治療、4DMt、治療載體進化和 4DMt 徽標均爲 4DMt 的商標。
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
我們所有的產品候選者都處於臨床或臨床前階段，並尚未獲得美國食品和藥物管理局（FDA）或任何其他監管機構的營銷批准。對於它們正在研究的治療用途的安全性或有效性，不發表任何聲明。
Learn more at and follow us on LinkedIn.
了解更多信息，請訪問並在LinkedIn上關注我們。
Contacts:
聯繫人：
Media:
媒體：
Katherine Smith
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
凱瑟琳·史密斯
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investors:
投資者：
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
朱利安·裴
投資者關係和企業財務負責人
Investor.Relations@4DMT.com